News | Radiation Therapy | June 29, 2017

Multiple market reports indicate that as doctors discover new ways to utilize Gamma Knife radiosurgery, the global market for this innovative surgical method is growing.

Multiple Uses for Gamma Knife to Drive Market Growth Through 2025

June 29, 2017 — Due to its widespread success in treating several types of brain cancer, global market growth for Gamma Knife radiosurgery involving the head is expected to exceed $364.8 million by 2025. As more patients seek treatment at facilities that offer Gamma Knife radiosurgery, the market is forecast to grow at a compound annual growth rate (CAGR) of 9.2 percent, according to a new report from public relations firm OpenPR.

In terms of geographical location, North America has traditionally led market revenue share, accounting for over 29.2 percent of revenue in 2014, according to the report. A separate report from Future Market Insights indicates that by 2025, treatment of brain metastasis is expected to account for over $285.7 million in the United States market alone. However, as more patients worldwide are treated using Gamma Knife for a variety of medical conditions (for example, brain metastases, benign brain tumors such as pituitary adenomas, meningiomas and acoustic neuromas), both the European and Asia Pacific markets are expected to expand at CAGRs of 7.7 percent and 10.5 percent, respectively.(1)

A large part of this growth is the confirmation of the Gamma Knife an effective treatment option for a wide variety of medical conditions that benefit from a precision approach. Beyond its use as a successful therapy for metastatic brain tumors, the Gamma Knife has provided powerful results to patients suffering from trigeminal neuralgia, movement disorders and arteriovenous malformations, according to the San Diego Gamma Knife Center.

Kenneth Ott, MD, FACS, neurosurgeon at SDGKC, said, “The need for the radiosurgical treatment of metastatic brain tumors is vast and growing. Radiosurgery will also play an important part in the emerging field of neuro-augmentation. Stereotactic functional neurosurgery for pain, obsessive compulsive disorders, seizure disorders and other functional brain disorders will provide further patients to Gamma Knife facilities.”

Additionally, as more patients become aware of the advantages of radiosurgery, there is an increasing demand for this minimally invasive surgical method which has proven to be painless and less time-consuming. Support from governmental agencies, which are increasingly interested in initiatives focused on advancing the practice of radiosurgery, will further drive market growth as more healthcare facilities receiving government funding turn to the practice, according to the FMI report.

“As the nationwide cost of medical care and facilities continued to increase, it is increasingly important to healthcare facilities to provide cost-efficient treatment, such as radiosurgery,” said Ott. “Single treatment in a few hours, in an outpatient facility avoids the cost of in-patient care and the complications necessitated by open surgery. Patients are increasingly aware that co-pay and deductible costs are reduced with Gamma Knife radiosurgery.”

For more information: www.sandiegogammaknife.com


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
Subscribe Now